Clinical Trial Update: Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of nitrocamptothecin for recurrent or metastatic ovarian cancer and primary peritoneal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Nitrocamptothecin (nitrocamptothecin)

Snippet

Sponsor: Gynecologic Oncology Group | Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer | Phase 2 | Status: WITHDRAWN